Prosecution Insights
Last updated: October 04, 2026

Dann, Dorfman, Herrell & Skillman

Technology area: Biotechnology & Pharmaceuticals

35 pending office actions • 21 clients • 34 examiners • 23 art units • 0 of 35 (0%) have an AI response strategy ready • 36 patents granted in the last 365 days

Analysis

DANN, DORFMAN, HERRELL & SKILLMAN is a patent law firm with 4407 career applications. The firm specializes in Biotechnology & Pharmaceuticals. It maintains a resolved allowance rate pct of 76.27. This performance is associated with an avg office actions per allowance of 3.46. The firm currently has 27 pending office actions.

The resolved allowance rate pct of 76.27 reflects the examination standards in the Biotechnology & Pharmaceuticals technology area. The firm's avg office actions per allowance of 3.46 indicates a prosecution style that involves interaction with the USPTO. Across 4407 career applications, these figures show a firm with experience in a technical field. The 27 pending office actions indicate a stream of active cases. For stakeholders, these metrics provide an expectation of the effort and success rates for this firm's work. The firm's 4407 career applications establish its long-term presence in Biotechnology & Pharmaceuticals.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=4407 apps, methodology: how we score firms)

76.3%
Allowance Rate
n=4407
+0.54σ
Allowance Rate (norm)
n=4407
3.5
OAs to Allowance
n=2484
-0.03σ
OAs to Allow (norm)
n=2484
1156 days
Time to Allowance
n=2484
+15.5pp
Interview Lift
n=4407
20.6%
RCE Rate
n=4407
1.3%
Appeal Rate
n=4407

Rejection Performance (% of received rejections ultimately overcome)

84.0%
§101 Overcome
n=269
80.7%
§102 Overcome
n=942
81.6%
§103 Overcome
n=1454
84.1%
§112 Overcome
n=1317

Specialization & Scale

A61K, A61P, C12N
Top CPC Subclasses
21%
Top-3 CPC Share
n=4407
0
Practitioners
n=4407
—
Apps / Practitioner
n=4407 (min 20)

Portfolio Summary

35
Total Pending OAs
24
Non-Final OAs
11
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 18 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

8
Overdue
0
Due this week
4
Due this month
3
Due in next 60 days
3
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 18 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (8)Due ≤ 30 days (4)Due ≤ 60 days (3)Due later (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

15
Hard (43%)
17
Medium (49%)
3
Easy (9%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only13 (37%)
§102 only1 (3%)
§112 only3 (9%)
Double-patenting + other3 (9%)
Multi-statute (no §101)15 (43%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

22
Life Sciences
63% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
2
Semiconductors
6% of docket
4
Mechanical / Eng
11% of docket
7
Business / Other
20% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

350 h
Manual time on pending OAs
70 h
Time saved (low, 20%)
122 h
Time saved (mid, 35%)
3.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
VIVLEMORE, TRACY ANN 2 73.0% +6.6%
NEGRON, ISMAEL 1 73.5% +15.1%
DAVIS, BRIAN J 1 84.8% -4.0%
GEMBEH, SHIRLEY V 1 63.2% +34.0%
PATEL, DEVANG R 1 65.6% +39.2%
LIANG, ANTHONY M 1 83.5% +9.5%
WONG, TINA MEI SENG 1 84.3% +14.4%
PACKARD, BENJAMIN J 1 66.7% +15.6%
PONCIANO, PATRICK BERNAS 1 57.0% +7.6%
ALLEY, GENEVIEVE S 1 60.3% +48.2%

Quick Wins (2)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18802192 High Strength, High Impact Toughness Steel Alloy, an Article of Manufacture Made Therefrom, and a Method of Making the Same LIANG, ANTHONY M —
18833167 AN APPARATUS WONG, TINA MEI SENG —

Hard Cases (15)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17783365 HIGH-THROUGHPUT DETECTION METHOD FOR RARE MUTATION OF GENE TURPIN, ZACHARY MARK 49d overdue
18033627 COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER SHIN, DANA H 37d overdue
18600263 NANOFIBER AND MICROFIBER HYBRID AEROGELS ALLEY, GENEVIEVE S 17d overdue
17786147 COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION PERSONS, JENNA L 16d overdue
18016025 SECURE, AUTOMATED, SYSTEM AND COMPUTER IMPLEMENTED PROCESS FOR MONITORING CARE PROVIDED TO A CONSUMER ACCORDING TO A PHARMACOLOGICAL OR NUTRITIONAL REGIMEN OF THE CONSUMER PORTER, RACHEL L 28d
18194664 NANOFIBER COLLECTION DEVICES VARGOT, MATHIEU D 43d
17800793 ELECTROCHROMIC DEVICE AND METHOD FOR PRODUCING THE SAME KING, GEORGE G 47d
18263391 IMPROVED ROLL-FORMED STRUCTURAL MEMBER FONSECA, JESSIE T 69d

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18600263 NANOFIBER AND MICROFIBER HYBRID AEROGELS ALLEY, GENEVIEVE S 17d overdue
18699799 REFILLABLE TISSUE ENGINEERED SCAFFOLDS PACKARD, BENJAMIN J 10d overdue
19400821 HAND HOLDABLE LIGHT AND BATTERY HAVING SYMMETRICAL CONTACTS NEGRON, ISMAEL —
18846364 METFORMIN NANOFORMULATIONS AND METHODS OF USE THEREOF GEMBEH, SHIRLEY V —
18811972 Alloy for Mud Motor Shaft Applications with High Strength, High Impact Toughness and Excellent Fatigue Life PATEL, DEVANG R —
18833167 AN APPARATUS WONG, TINA MEI SENG —

Client Portfolio (21 clients)

Top Art Units

Art UnitApps
16172
16112
16562
16382
16372
28751
17341
16121
36341
16541

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19400821 HAND HOLDABLE LIGHT AND BATTERY HAVING SYMMETRICAL CONTACTS Streamlight, Inc. NEGRON, ISMAEL 2875 §102§103§112 Non-Final OA — Pending Nov 25, 2025
18987189 GROWTH FACTOR LOADED NANOFIBERS AND METHODS OF USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA DAVIS, BRIAN J §102§103§112 Non-Final OA — Pending Dec 19, 2024
18846364 METFORMIN NANOFORMULATIONS AND METHODS OF USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA GEMBEH, SHIRLEY V §102§103 Non-Final OA — Pending Sep 12, 2024
18811972 Alloy for Mud Motor Shaft Applications with High Strength, High Impact Toughness and Excellent Fatigue Life Crs Holdings, LLC PATEL, DEVANG R §103§112 Non-Final OA — Pending Aug 22, 2024
18802192 High Strength, High Impact Toughness Steel Alloy, an Article of Manufacture Made Therefrom, and a Method of Making the Same Crs Holdings, LLC LIANG, ANTHONY M 1734 §103 Non-Final OA — Pending Aug 13, 2024
18833167 AN APPARATUS Duality Quantum Photonics Ltd. WONG, TINA MEI SENG §112 Non-Final OA — Pending Jul 25, 2024
18699799 REFILLABLE TISSUE ENGINEERED SCAFFOLDS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA PACKARD, BENJAMIN J 1612 §103 Non-Final OA 10d overdue Pending Apr 09, 2024
18696443 Improved Sliding Door Cavity Sliders Limited PONCIANO, PATRICK BERNAS 3634 §103 Non-Final OA — Pending Mar 28, 2024
18600263 NANOFIBER AND MICROFIBER HYBRID AEROGELS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA ALLEY, GENEVIEVE S 1617 §102§103§112 Final Rejection 17d overdue Pending Mar 08, 2024
18681728 THERAPEUTIC COMPOSITIONS AND RELATED METHODS Cornell University SHIAO, YIH-HORNG §102§103§112 Non-Final OA — Pending Feb 06, 2024
18409324 DRIVER CIRCUIT AND METHOD FOR A SEMICONDUCTOR LASER Streamlight, Inc. CAMACHO ALANIS, FERNANDA ADRIANA §112 Non-Final OA — Pending Jan 10, 2024
18510115 METHODS AND COMPOSITIONS FOR PERTUSSIS DIAGNOSIS Dx Discovery Inc. ESSEX, LAURA ANN §112DP Non-Final OA — Pending Nov 15, 2023
18287762 CYCLOSPORINE COMPOSITIONS AND METHODS OF USE THEREOF Protransit Nanotherapy LLC HOERNER, PAUL ELLSWORTH 1611 §103 Final Rejection 87d overdue Pending Oct 20, 2023
18278865 Antimicrobial Peptides BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA JAUHARI, SACHI 1654 §103Other Non-Final OA — Pending Aug 25, 2023
18263391 IMPROVED ROLL-FORMED STRUCTURAL MEMBER Formsteel Technologies Limited FONSECA, JESSIE T 3633 §102§103§112 Final Rejection 69d Pending Jul 28, 2023
18253121 Marine Vessel Fender and Control System C W F Hamilton & Co. Limited PANDE, ASHUTOSH 3668 §103§112 Final Rejection — Pending May 16, 2023
18033627 COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER The Children's Hospital of Philadelphia SHIN, DANA H 1635 §102§112 Final Rejection 37d overdue Pending Apr 25, 2023
18194664 NANOFIBER COLLECTION DEVICES BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA VARGOT, MATHIEU D 1742 §103§112 Non-Final OA 43d Pending Apr 03, 2023
18246572 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HAIR LOSS AND OTHER CONDITIONS Protransit Nanotherapy LLC VARADARAJ, ARCHANA 1658 §103DP Final Rejection 4d overdue Pending Mar 24, 2023
18176546 Compositions and Methods for Modulating Factor IX Function The Children's Hospital of Philadelphia TSAY, MARSHA M 1656 §103 Non-Final OA 73d overdue Pending Mar 01, 2023
18021956 AMMONOLYSIS SOLUTION AND AMMONOLYSIS METHOD Genewiz Inc., Sz LEE, HOI YAN NMN 1693 §103 Non-Final OA 63d Pending Feb 17, 2023
18016025 SECURE, AUTOMATED, SYSTEM AND COMPUTER IMPLEMENTED PROCESS FOR MONITORING CARE PROVIDED TO A CONSUMER ACCORDING TO A PHARMACOLOGICAL OR NUTRITIONAL REGIMEN OF THE CONSUMER Blunergy S.A. PORTER, RACHEL L 3684 §103§112 Non-Final OA 28d Pending Jan 13, 2023
18008422 USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR Children'S National Medical Center VIVLEMORE, TRACY ANN 1638 §103 Final Rejection 28d Pending Dec 05, 2022
17938857 Compositions and Methods for Treating Huntington's Disease and Related Disorders The Children's Hospital of Philadelphia GOMEZ RODRIGUEZ, JULIO WASHINGTON 1637 §102 Final Rejection 40d Pending Oct 07, 2022
17905407 CRISPR/CAS9 SYSTEM FOR MULTISTRAIN HIV-1 TREATMENT BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA VIVLEMORE, TRACY ANN 1638 §103 Non-Final OA 28d Pending Aug 31, 2022
17800793 ELECTROCHROMIC DEVICE AND METHOD FOR PRODUCING THE SAME Freshape SA KING, GEORGE G 2872 §102§103 Non-Final OA 47d Pending Aug 18, 2022
17795604 COMPOSITIONS AND METHODS FOR COATING BONE GRAFTS UNIVERSITY OF ROCHESTER BOECKELMAN, JACOB A 1655 §103 Non-Final OA — Pending Jul 27, 2022
17786147 COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION The Trustees of the University of Pennsylvania PERSONS, JENNA L 1637 §103§112 Non-Final OA 16d overdue Pending Jun 16, 2022
17783365 HIGH-THROUGHPUT DETECTION METHOD FOR RARE MUTATION OF GENE Suzhou Smk Gene Tech Ltd. TURPIN, ZACHARY MARK 1682 §103§112 Non-Final OA 49d overdue Pending Jun 08, 2022
17777245 COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION The Children's Hospital of Philadelphia MCKNIGHT, CIARA A 1656 §103DP Non-Final OA — Pending May 16, 2022
17694841 Viral Vectors for Prophylaxis and Therapy of Hemoglobinopathies The Children's Hospital of Philadelphia MARVICH, MARIA 1634 §112 Non-Final OA — Pending Mar 15, 2022
17621927 COMPOSITIONS AND METHODS FOR ENHANCING PLANT GROWTH BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. PALLAY, MICHAEL B 1617 §102§103 Final Rejection — Pending Dec 22, 2021
17532123 COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION Cold Spring Harbor Laboratory IANNUZO, NATALIE NMN 1653 §103 Non-Final OA — Pending Nov 22, 2021
17425130 WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEROF Children'S National Medical Center MIDDLETON, DANAYA L 1674 §103 Final Rejection 28d Pending Jul 22, 2021
16972727 METHOD FOR PREPARING COMPOSITION COMPRISING KILLED OR INACTIVATED METHANOBREVIBACTER ARCHAEBACTERIA CELLS AND COMPOSITION THEREBY OBTAINED Duncan-Bruce Sutherland ALAM, AYAAN A 1611 §103 Final Rejection 70d Pending Dec 07, 2020

Managing Dann, Dorfman, Herrell & Skillman's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month